PL326636A1 - Derivatives of quinoline as inhibitors of type iv phosphodiesterase - Google Patents

Derivatives of quinoline as inhibitors of type iv phosphodiesterase

Info

Publication number
PL326636A1
PL326636A1 PL96326636A PL32663696A PL326636A1 PL 326636 A1 PL326636 A1 PL 326636A1 PL 96326636 A PL96326636 A PL 96326636A PL 32663696 A PL32663696 A PL 32663696A PL 326636 A1 PL326636 A1 PL 326636A1
Authority
PL
Poland
Prior art keywords
phosphodiesterase
quinoline
inhibitors
derivatives
type
Prior art date
Application number
PL96326636A
Other languages
English (en)
Inventor
Rainer Lueoend
Villar Esteban Pombo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL326636A1 publication Critical patent/PL326636A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL96326636A 1995-11-14 1996-11-13 Derivatives of quinoline as inhibitors of type iv phosphodiesterase PL326636A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523267.4A GB9523267D0 (en) 1995-11-14 1995-11-14 Organic compounds
PCT/EP1996/004978 WO1997018208A1 (en) 1995-11-14 1996-11-13 Quinoline derivatives as type iv phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
PL326636A1 true PL326636A1 (en) 1998-10-12

Family

ID=10783856

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96326636A PL326636A1 (en) 1995-11-14 1996-11-13 Derivatives of quinoline as inhibitors of type iv phosphodiesterase

Country Status (17)

Country Link
EP (1) EP0873338A1 (xx)
JP (1) JPH11515000A (xx)
KR (1) KR19990067574A (xx)
CN (1) CN1202170A (xx)
AU (1) AU7570996A (xx)
BR (1) BR9611504A (xx)
CA (1) CA2235126A1 (xx)
CO (1) CO4770973A1 (xx)
CZ (1) CZ149498A3 (xx)
GB (1) GB9523267D0 (xx)
HU (1) HUP9903492A3 (xx)
MX (1) MX9803839A (xx)
PE (1) PE17598A1 (xx)
PL (1) PL326636A1 (xx)
SK (1) SK63998A3 (xx)
TR (1) TR199800851T2 (xx)
WO (1) WO1997018208A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
WO2002094321A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
GEP20084439B (en) * 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
JP2006347936A (ja) 2005-06-15 2006-12-28 Bayer Cropscience Ag 殺虫性ベンズアニリド類
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
MX358508B (es) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3813532B1 (en) * 2018-06-24 2024-02-28 Adama Agan Ltd. Process for the preparation of quinmerac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines

Also Published As

Publication number Publication date
CN1202170A (zh) 1998-12-16
MX9803839A (es) 1998-09-30
HUP9903492A2 (en) 2000-07-28
BR9611504A (pt) 1999-03-02
TR199800851T2 (xx) 1998-08-21
CO4770973A1 (es) 1999-04-30
EP0873338A1 (en) 1998-10-28
KR19990067574A (ko) 1999-08-25
SK63998A3 (en) 1998-10-07
WO1997018208A1 (en) 1997-05-22
JPH11515000A (ja) 1999-12-21
CZ149498A3 (cs) 1998-08-12
HUP9903492A3 (en) 2000-08-28
AU7570996A (en) 1997-06-05
CA2235126A1 (en) 1997-05-22
PE17598A1 (es) 1998-04-06
GB9523267D0 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
PL327185A1 (en) Thyrosine derivatives as inhibitors of integrin-alpha v
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL326967A1 (en) Quinoline derivatives
PL326636A1 (en) Derivatives of quinoline as inhibitors of type iv phosphodiesterase
PL324819A1 (en) Derivatives of 4-mercaptopyrrolidine as inhibitors of farnesil transferase
PL327569A1 (en) Promedications of thrombosin inhibitors
AU6419296A (en) Cyclic gmp-specific phosphodiesterase inhibitors
PL313541A1 (en) Derivatives of quinazoline
PL323066A1 (en) Derivatives of quinazoline
IL135673A0 (en) Therapeutic uses of quinoline derivatives
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
IL141445A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
AU7168696A (en) Inhibitors of regulatory pathways
GB9603723D0 (en) Diphenyl pyridyl derivatives as pde iv inhibitors
AU4756696A (en) Compounds for and method of inhibiting phosphodiesterase iv
PL324106A1 (en) Derivatives of benzo [g] quinoline
AU3039995A (en) Heterocyclic derivatives of N-phenylamides
AU2274299A (en) Benzazine derivatives phosphodiesterase 4 inhibitors
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
PL325122A1 (en) Bicyclic derivatives of 4-aralkylamino pyrididine as inhibitors of thyrosinic kinase
PL324034A1 (en) Tribenzimidazoles useful as inhibitors of topoisomerase i
PL326927A1 (en) Salts of quinolin derivatives as nk3 antagones
IL141446A0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
AU3075595A (en) Anti-helicobacter heterocyclic derivatives of azolones
AP2000001767A0 (en) Method for synthesis of quinoline derivatives